Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Nursel Sürmelioğlu und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Amides, Pyrazines, COVID-19 Drug Treatment, Antiviral Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Sürmelioğlu, N., Demirtürk, E., Ateş Ayhan, N., Özel Yeşilyurt, A., Bayrakçi, S., Kaynak, M. S., Özyılmaz, E., & Allegaert, K. (2024). Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204496
Vancouver
Sürmelioğlu N, Demirtürk E, Ateş Ayhan N, Özel Yeşilyurt A, Bayrakçi S, Kaynak MS, et al. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204496
BibTeX
@article{Srmeliolu2024,
author = {Sürmelioğlu, Nursel and Demirtürk, Esra and Ateş Ayhan, Nazire and Özel Yeşilyurt, Aysun and Bayrakçi, Sinem and Kaynak, Mustafa Sinan and Özyılmaz, Ezgi and Allegaert, Karel},
title = {Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204496}
}
EUVIMED